- Trial phase
- Phase 1
- Time to market
- At least 5-7 years, assuming successful Phase 1 safety data, progression through Phase 2/3, and regulatory approval. The drug is currently in early Phase 1 with dosing just initiated.
- Why 4/10
- No hard dated binary catalyst (pivotal readout, PDUFA, or AdComm) is scheduled for RP-A701 in the next ~12 months. The drug is in early Phase 1 testing with dosing just initiated; initial data readout timing has not been guided. It is one of several pipeline programs at Rocket, where the lead value driver is RP-A501 (Danon disease, pivotal Phase 2). ImpactScore is 4, reflecting an early-stage asset with no near-term binary event.
The next catalyst for RP-A701 is initial safety and tolerability data from the Phase 1 study, though no specific readout date has been guided. Positive early data would validate Rocket's cardiovascular gene therapy platform beyond the lead RP-A501 program. However, the competing Affinia Therapeutics AFTX-201 program (Phase 1/2) is a direct rival and has already received FDA Fast Track and orphan drug designations, creating a competitive overhang.
Price Chart
Executive Summary
RP-A701 is Rocket Pharmaceuticals' preclinical-to-early-clinical gene therapy candidate for BAG3-associated dilated cardiomyopathy (BAG3-DCM), a severe genetic heart condition. It uses an AAVrh.74 vector to deliver a functional BAG3 gene to heart muscle cells. The FDA cleared its IND in June 2025, and as of Rocket's Q3 2026 earnings report (November 12, 2026), dosing has been initiated in the Phase 1 study. The EMA granted orphan designation in October 2026. RP-A701 is one of three cardiovascular gene therapies in Rocket's pipeline, behind the lead RP-A501 (Danon disease, pivotal Phase 2). A direct competitor, Affinia Therapeutics' AFTX-201, is already in Phase 1/2 trials with FDA Fast Track and orphan drug designations. RP-A701 is early-stage with no near-term binary catalyst, making it a small part of Rocket's overall value story.
How It Works
RP-A701 is a gene therapy that uses a harmless adeno-associated virus (AAVrh.74) as a delivery vehicle to carry a working copy of the BAG3 gene into heart muscle cells. In people with BAG3-associated dilated cardiomyopathy, mutations in the BAG3 gene cause the heart to progressively enlarge and weaken, leading to heart failure. The therapy is given as a one-time IV infusion, aiming to restore the missing protein and stop or reverse the disease.
Trial Status
FDA IND cleared June 30, 2025. First patient dosing was anticipated in mid-2026, and as of Rocket's Q3 2026 report (November 12, 2026), dosing has been initiated in the Phase 1 study. No clinical data have been reported yet.
The Two-Sided Case
Upcoming Catalysts
- Initial Phase 1 safety and tolerability data (timing not yet guided)
- Potential Phase 1 interim efficacy signals (timing not yet guided)
- Competitive landscape updates from Affinia Therapeutics' AFTX-201 Phase 1/2 UPBEAT trial data
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ROCKET PHARMACEUTICALS, INC. CLUSTER RCKT ·Originating report